

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---|-----------------|-----------------------|---------------------------|------------------|
| 10/718,411 | 11/20/2003 | Arlindo L. Castelhano | 60390-IB/JPW/GJG/JBC 1528 | |
| 38724 | 7590 01/13/2006 | EXAMINER | | INER |
| OSI PHARMACEUTICALS, INC. | | | PRYOR, ALTON NATHANIEL | |
| 58 SOUTH SERVICE ROAD MELVILLE, NY 11747 | | | ART UNIT | PAPER NUMBER |
| ,, | | | 1616 | |
| | | | DATE MAILED: 01/13/2006 | |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | Application No. | Applicant(s) | | | |
|--|---|-------------------|--|--|--|
| | 10/718,411 | CASTELHANO ET AL. | | | |
| Office Action Summary | Examiner | Art Unit | | | |
| | Alton N. Pryor | 1616 | | | |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply | | | | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). | | | | | |
| Status | | | | | |
| Responsive to communication(s) filed on 18 Oct This action is FINAL. 2b)⊠ This Since this application is in condition for alloware closed in accordance with the practice under E | action is non-final. nce except for formal matters, pro | | | | |
| Disposition of Claims | | | | | |
| 4) Claim(s) 42-50 and 54-59 is/are pending in the 4a) Of the above claim(s) is/are withdraw 5) Claim(s) 46-50 and 54-59 is/are allowed. 6) Claim(s) 42-45 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or | vn from consideration. | | | | |
| Application Papers | | | | | |
| 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). | | | | | |
| Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. | | | | | |
| Priority under 35 U.S.C. § 119 | | | | | |
| 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. | | | | | |
| Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 3-14/05;11/20/03. | 4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa | | | | |

Application/Control Number: 10/718,411 Page 2

Art Unit: 1616

DETAILED ACTION

Applicant's arguments, see paper, filed 10/18/05, with respect to double patenting rejection have been fully considered and are persuasive. The rejection of record has been withdrawn. Double Patenting Rejection of claims 54-59 over USPN 6664252 will not be maintained in light of amendment filed 10/18/05.
Applicant has provided a Terminal Disclaimer to overcome this rejection.

II. New Ground of Rejection below.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 42-45 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for employing adenosine compounds for treating conditions specified in the claims, does not reasonably provide enablement for using instant two adenosine compounds for treating the group of unrelated diseases recited in the claims. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims. Because many of the diseases are unrelated, the mechanism of treating the diseases may differ and therefore is questionable. The predictability in this art is high since unrelated diseases come about differently. As a result, the mechanism of drug treatment is disease dependent and therefore may vary from disease to disease. To one of ordinary skill in the art, it would

Application/Control Number: 10/718,411 Page 3

Art Unit: 1616

be a big job to determine the mechanism of how the instant compounds (drugs) are effectively used to treat each disease type since Applicant provides no Examples for guidance. Because of this large burden, Applicant is entitled to a subgenus of diseases. Examiner stresses that the subgenus created should be a group of related diseases in terms of physiology.

III. Claims 46-50,54-59 are allowable. The prior art does not teach or suggest the instant compounds being employed in a composition or in a method of inhibiting activity of an A1 adenosine receptor in a cell.

Telephonic Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alton N. Pryor whose telephone number is 571-272-0621. The examiner can normally be reached on 8:00 a.m. - 4:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/718,411

Art Unit: 1616

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Page 4

Alton Pryor

Primary Examiner

AU 1616